Infectious Disease CRO

Welcome to IBT Bioservices

State-of-the-art Infectious Disease CRO

Research Reagents & Assay Services

Soluble Spike Protein, Soluble Receptor Binding Domain

Pseudotyped Spike Neutralization Assay Services for Variants of Concern

Zika Testing Capabilities

in vitro assays & animal model now available

Trusted expertise

in design and implementation of early research and translational product development

Nipah Virus Glycoprotein

recombinant attachement G protein, Bangladesh strain

NEW Research Reagents!

Hemagglutination Inhibition (HAI) Testing

For 2022/2023 Seasonal Influenza Vaccine Strains

Now Available

IN VITRO ANTIVIRAL TESTING

Well-characterized assays for a growing selection of viruses Now Available! VSV-SARS-CoV2 Neutralization Assay

In Vitro Antibacterial Testing

Assays for a wide selection of gram-positive and gram-negative bacteria

PURCHASE REAGENTS

Now Available! New Reagents for Coronavirus research Full-Length Spike Protein, Soluble Receptor Binding Domain, Nucleocapsid Protein, and Polyclonal Antibodies.

Animal Models

Antiviral & antibacterial disease models – Immunogenicity testing, Pharmacokinetics & toxicity

Assay & Protein Services

Custom development, analysis and expression services

About IBT

The IBT Bioservices mission is to provide top client value by applying our infectious disease expertise, collaborative scientific interaction, and a flexible, cost-effective business model. The result is timely and relevant data for our clients’ needs.

Our scientists are leaders in their areas and can provide the highest level of expertise for your R&D programs. Read more about IBT.

Spotlight On:

M. Javad Aman, PhD, President and CEO of Integrated BioTherapeutics, discusses his Montgomery County-based company’s R&D mission to develop vaccines and therapies to combat emerging infectious diseases.

IBT can help you identify lead candidates with our in vitro screening assays

A key step in drug discovery is screening assays to assess antiviral activity. We offer a set of assays in key virus families. We can help you select appropriate assays for your specific compound and mechanism of action. We perform cytotoxicity analysis of the compounds to ensure your efficacy data are meaningful and within a reasonable therapeutic window. We can develop custom assays tailored to your specific program.

Test your compounds in IBT’s Dengue Virus Mouse Model

IBT Bioservices’ Dengue Virus AG129 mouse model using the D2Y98P dengue clinical isolate is an attractive platform for assessing the efficacy of dengue (DENV) drug and vaccine candidates. This is a lethal model which uses a unique non-mouse-adapted strain of DENV serotype 2 (D2Y98P), isolated from a DENV-infected patient in Singapore, which is highly infectious in AG129 mice. The model is based on the publication of Tan et al. 2010. The model provides consistent clinical manifestations of disease that are similar to human cases.

Learn more about IBT’s Filovirus GP VSV-pseudotyped Assay

Pseudotyped virus was pre-incubated with KZ52 (EBOV-VSV), 16F6 (SUDV-VSV) or anti-MARV IgG (MARV)VSV for 1 hour before adding virus to vero cells overnight. After 24 hours, cells are lysed and percent of infection was determined by luciferase intensity. Neutralization was determined relative to the untreated virus controls. In dose response experiments the concentration of antibody causing 50% neutralization (IC50) will be determined.

Check out IBT’s Zika animal model!

This model is developed in AG129 mice (Age 6-10 weeks). A biologically relevant model with a many advnatages. Available readouts including survival, weight change, health score, serum viremia, and tissue viremia can be tested. Contact us for additional details about testing your vaccine or therapeutic.

Ask us about our Influenza Animal Models!

IBT Bioservices has developed several mouse models of Influenza infection wherein mice are inoculated intranasally with an LD90 dose of virus. Test articles are administered per client instruction, and positive controls are available for comparison. Routine study endpoints include: lethality health score, weight, temperature, viral burden in lungs / BALF, cytokine response. our challenge virus seeds are well characterized and lead to highly reproducible lethality rates. To demonstrate this characterization, a meta-analysis was performed on over 30 groups challenged with an LD90 of the IFV A/Texas/36/91 (H1N1) strain (~52 PFU). The result was an average 12.4% survival rate (very near the theoretical 10%) with a mean time to death of 8.2 days.